Technical Analysis for APRE - Aprea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 19.5 0.88% 0.17
APRE closed up 0.88 percent on Wednesday, October 16, 2019, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical APRE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
NR7 Range Contraction 0.88%
NR7-2 Range Contraction 0.88%
Inside Day Range Contraction 0.88%
Hot IPO Pullback Bullish Swing Setup 0.72%
NR7 Range Contraction 0.72%
Hot IPO Pullback Bullish Swing Setup 2.52%
Inside Day Range Contraction 0.31%

Older signals for APRE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Biopharmaceutical Cancer Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Lactams Myelodysplastic Syndromes Anti Cancer Therapies P53 Tumor Suppressor Tumor Suppressor Genes
Is APRE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.61
52 Week Low 15.1
Average Volume 81,078
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 19.445
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.36
Resistance 3 (R3) 20.32 20.00 20.21
Resistance 2 (R2) 20.00 19.78 20.02 20.16
Resistance 1 (R1) 19.75 19.65 19.88 19.79 20.12
Pivot Point 19.43 19.43 19.49 19.45 19.43
Support 1 (S1) 19.18 19.21 19.31 19.22 18.88
Support 2 (S2) 18.86 19.08 18.88 18.84
Support 3 (S3) 18.61 18.86 18.79
Support 4 (S4) 18.65